Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clinuvel Pharmaceuticals Limited ( (AU:CUV) ) has issued an update.
CLINUVEL Pharmaceuticals has reported its highest December half-year profit to date, marking seventeen consecutive half-year profits. The company achieved a 10.5% revenue growth and a 48.1% increase in underlying profit before tax, with a focus on expanding its presence in North America, particularly in the underserved markets of vitiligo and the development of NEURACTHEL®. Despite a temporary dip in share price due to forced sellers, the company anticipates a strong rebound as it continues to share commercial and clinical progress with the market. CLINUVEL is actively seeking a new CEO, preferably an American, to lead its next growth phase, and is hosting a significant presence at the American Academy of Dermatology Annual Meeting to boost its prominence in North America.
More about Clinuvel Pharmaceuticals Limited
CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for specialized populations. The company is a pioneer in photomedicine and melanocortin peptides, with its lead therapy, SCENESSE®, approved for preventing phototoxicity in patients with erythropoietic protoporphyria (EPP) in several regions including Europe, the USA, Israel, and Australia.
YTD Price Performance: -11.24%
Average Trading Volume: 330
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $360.5M
For a thorough assessment of CUV stock, go to TipRanks’ Stock Analysis page.